Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
CinFina Pharma, a CinRx portfolio developing a portfolio of treatment options for obesity, has presented positive top-line interim results from its Phase I single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109. 4 November 2024
Pharmaceutical
Texas-based biopharma Lexicon Pharmaceuticals was trading nearly 36% lower on Friday morning. 1 November 2024
Exclusive
Most Read
Recent News
Pharmaceutical
CinFina Pharma, a CinRx portfolio developing a portfolio of treatment options for obesity, has presented positive top-line interim results from its Phase I single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109. 4 November 2024
Pharmaceutical
Texas-based biopharma Lexicon Pharmaceuticals was trading nearly 36% lower on Friday morning. 1 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Novartis late yesterday revealed that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). 30 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Insights
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 1 November 2024
Generics
31 October 2024 Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch.
Pharmaceutical
23 October 2024 Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had.
Biotechnology
21 October 2024 As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth.
Pharmaceutical
18 October 2024 An Expert View from Nick Petschek, Managing Director EMEA, Kotter International.
Biotechnology
16 October 2024 Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls.
Biotechnology
15 October 2024 Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs.
In Brief
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
One to Watch Companies
A clinical stage biopharma company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity.
A clinical-stage biotech compan developing cyclodextrin-based products for the treatment of neurodegenerative diseases.
A late-stage biopharma company addressing significant unmet need in the treatment of cardiometabolic diseases.
A clinical-stage in vivo gene editing company developing next generation precision genetic medicines.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze